Key Dates

Related Announcements

• February 2, 2024 - Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH). See NOSI NOT-AI-24-007.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

 The purpose of this Notice is to inform potential applicants that effective immediately the National Heart, Lung, and Blood Institute (NHLBI) will participate in NOT-AI-24-007 “Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)".

The following text has been added in bold and italics to reflect NHLBI's participation:

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

National Center for Advancing Translational Sciences (NCATS)

National Cancer Institute (NCI)

National Heart, Lung, and Blood Institute (NHLBI)

Research Topics of Interest

NHLBI

The NHLBI provides global leadership for research, training, and education programs to promote the prevention, diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases and enhance the health of all individuals so that they can live healthy and lead productive and fulfilling lives. The NHLBI invites SBIR/STTR applications focused on targeted delivery to specific tissue types that can enhance the therapeutic outcome while minimizing adverse effects on healthy tissues, such as immunogenicity, for HLBS diseases or conditions. Fast-Track and Phase II applications should include a regulatory plan if applicable to the proposed product commercialization. 

Examples of topics of interest within the scope of this NOSI include but are not limited to: 

• Targeted delivery approaches for addressing cardiovascular diseases such as atherosclerosis, hypertension and heart failure
• Targeted delivery approaches to treat damaged heart tissue 
• Non-viral delivery of gene editing systems (such as CRISPR/Cas9) for genetic HLBS disorders editing of hematopoietic stem cells ( HSCs) etc. 
• Targeted RNA delivery and CRSPR/Cas gene editing for the selected inhibition of genes such as PCSK9
• Targeted RNA therapeutics for lung diseases including idiopathic pulmonary fibrosis (IPF), asthma, chronic obstructive pulmonary disease (COPD), alpha-1 anti-trypsin deficiency, primary ciliary dyskinesia, cystic fibrosis and inborn errors of autoimmunity with pulmonary manifestations
• Targeted therapeutics to selectively modulate gene expression to correct underlying genetic abnormalities in blood disorders such as Sickle Cell Disease (SCD), hemophilia or promote the production of healthy blood cells
• Novel delivery approaches for lung delivery that can target any of the diverse cell types within the lung with high precision
• Non-viral therapeutic delivery systems for cardiopulmonary diseases that may be delivered via inhalation
• AI/ML approaches for optimizing targeted nanoparticles, delivery strategies, and for personalized predictions for accelerating the pre-clinical development of targeted RNA therapeutics for HLBS areas

IInquiries

Please direct all inquiries to the contacts in Section VII of the listed notice of funding opportunity with the following additions/substitutions:

Scientific/Research Contact(s)

Jain Krotz, Ph.D.
Innovation and Commercialization Office
Division of Extramural Research Activities
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-435-7677
Email:  jain.krotz@nih.gov

All other aspects of the NOSI remain the same.

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)

Jain Krotz, Ph.D.
Innovation and Commercialization Office
Division of Extramural Research Activities
National Heart Lung and Blood Institute (NHLBI)
Telephone: 301-435-7677
Email: jain.krotz@nih.gov

Financial/Grants Management Contact(s) 

Andre Walker
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8061 
Email: WalkerA@nhlbi.nih.gov